Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome

NCT06026787 is registered in ClinicalTrials.gov with Ain Shams University as lead sponsor.

NCT NCT06026787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06026787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome
Lead sponsor
Ain Shams University
Phase
Phase 4
Overall status
Completed
Start date
August 1, 2022
Completion date
August 1, 2023
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nephrotic syndrome, sodium-glucose transporter 2 inhibitors